Ignite Creation Date:
2024-05-06 @ 3:18 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04581876
Status:
UNKNOWN
Last Update Posted:
2020-10-09
First Post:
2020-06-30
Brief Title:
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Single-arm Prospective Study to Evaluate the Safety and Efficacy and of the Combination of Raltitrexed for Injection and Nab-Paclitaxel as Second-line Therapy in Treating Patients With Advanced Pancreatic Cancer
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study is intended to investigate the safety and efficacy of the patients with confirmed advanced pancreatic cancer after treating with the combination of raltitrexed for injection and nab-paclitaxel
Detailed Description:
Conditions Advanced pancreatic cancer subjects which were prospectively to receive first-line chemotherapy
Keywords Advanced pancreatic cancer paclitaxel liposome S-1 Interventions Drug paclitaxel liposome DrugS-1 Phase Phase IV Study Type Interventional
Study Design
Allocation Non-randomized Endpoint Classification Efficacy Safety Study Intervention Model single arm Primary Purpose Treatment MedlinePlus related topics Cancer Pancreatic Cancer Drug Information available for paclitaxel liposomepaclitaxel liposome for injection S-1Tegafur Gimeracil and Oteracil Potassium Capsules
Primary Outcome Measures
To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1
Secondary Outcome Measures
To evaluate the Overall Response Rateoverall survivaldisease control rateQuality of Lifeadverse events of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1
Keywords Advanced pancreatic cancer paclitaxel liposome S-1 Interventions Drug paclitaxel liposome DrugS-1 Phase Phase IV Study Type Interventional
Study Design
Allocation Non-randomized Endpoint Classification Efficacy Safety Study Intervention Model single arm Primary Purpose Treatment MedlinePlus related topics Cancer Pancreatic Cancer Drug Information available for paclitaxel liposomepaclitaxel liposome for injection S-1Tegafur Gimeracil and Oteracil Potassium Capsules
Primary Outcome Measures
To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1
Secondary Outcome Measures
To evaluate the Overall Response Rateoverall survivaldisease control rateQuality of Lifeadverse events of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None